Recombinant Mouse IL-27 Ra/WSX-1/TCCR Fc Chimera Protein, CF

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse IL-27 Ra/WSX-1/TCCR Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit IL-27 anti-viral activity using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Bender H. et al. (2009) Hepatology 50:585. The ED₅₀ for this effect is 2‑12 µg/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse IL-27 R alpha/WSX-1/TCCR protein
  

  Mouse IL-27 R alpha (Gly29-Lys510) Accession # O70394	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: O70394
• N-terminal Sequence: Gly29
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: Il27ra
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 80 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 105-115 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse IL-27 Ra/WSX-1/TCCR Fc Chimera Protein, CF

• class I cytokine receptor
• CRL1IL-27R
• Cytokine receptor-like 1
• IL-27 R alpha
• IL27R alpha
• IL27R
• IL27RA
• IL-27Ra
• IL-27R-alpha
• interleukin 27 receptor, alpha
• interleukin-27 receptor subunit alpha
• TCCR
• TCCRIL-27 receptor subunit alpha
• T-cell cytokine receptor type 1
• Type I T-cell cytokine receptor
• WSX-1
• WSX1IL-27R subunit alpha
• zcytor1

Background

IL‑27 R alpha (also known as WSX‑1 and TCCR) is a 85‑95 kDa member of the type I, group 2 cytokine receptor family (1‑6). Mature IL‑27 R alpha is a type I transmembrane glycoprotein that contains a 486 amino acid (aa) extracellular region, a 21 aa transmembrane segment and a 92 aa cytoplasmic domain. Consistent with type I cytokine receptors, the extracellular region contains four positionally conserved cysteine residues, a WSxWS motif (for receptor folding and ligand binding), and three fibronectin type III repeats. The intracellular domain contains a “box‑1” motif that may be involved with Janus kinases (3). In mouse, a soluble 33 kDa splice form that shows a 20 aa substitution for aa 251‑623 has been identified (7). The mouse IL‑27 R alpha extracellular region shares 63% amino acid identity with the human IL‑27 R alpha extracellular domain (2, 3). IL‑27 R alpha is expressed in mast cells, endothelial cells, NK cells, macrophages, monocytes, B cells, dendritic cells, and naïve T cells (1, 2, 4, 8). Typical of other class I cytokine receptor chains, the ligand binding IL‑27 R alpha molecule is known to heterodimerize with a signal‑transducing subunit (gp130) to form a functional IL‑27 receptor (9, 10). In addition, IL‑27 R alpha is reported to complex with CNTFR alpha and gp130 form a humanin receptor on neurons (7, 11), and to complex with gp130 and IL‑6 R to form a receptor for a p28:CLF heterodimeric cytokine on lymphocytes (12). Studies using IL‑27 R alpha /WSX‑1^-/- mice reveal that IL‑27 has the ability to suppress T cell activity during infection, and to mediate an inhibition of both type 1 and type 2 T cell immunity (4, 13, 14). In particular, IL‑27 is known to act on naïve T cells, blocking their differentiation into a Th17 phenotype. Notably, cells committed to a Th17 phenotype, although they express a functional IL‑27 receptor, are unresponsive to the effects of IL‑27 (15). Activated T cells that are CD4⁺ and CD8⁺, and which express the IL‑27 receptor, can be induced by IL‑27 to form a double‑positive CD25⁺ FoxP3^- IFN‑ gamma plus IL‑10 secreting phenotype that both promotes and suppresses the inflammatory response (16).

1. Villarino, A.V. et al. (2004) J. Immunol. 173:715.
2. Chen, Q. et al. (2000) Nature 407:916.
3. Sprecher, C.A. et al. (1998) Biochem. Biophys. Res. Commun. 246:82.
4. Artis, D. et al. (2004) J. Immunol. 173:5626.
5. Yoshida, H. and Y. Miyazaki (2008) Int. J. Biochem. Cell Biol. 40:2379.
6. Yoshida, H. and M. Yoshiyuki (2008) Immunol. Rev. 226:234.
7. Hashimoto, Y. et al. (2009) Biochem. Biophys. Res. Commun. 389:95
8. Holscher, C. et al. (2005) J. Immunol. 174:3534.
9. Pflanz, S. et al. (2004) J. Immunol. 172:2225.
10. Scheller, J. et al. (2005) Biochem. Biophys. Res. Commun. 326:724.
11. Hashimoto, Y. et al. (2009) Mol. Biol. Cell 20:2864.
12. Crabe, S. et al. (2009) J. Immunol. 183:7692.
13. Villarino, A. et al. (2003) J. Immunol. 170:645.
14. Hamano., S. et al. (2003) Immunity 19:657.
15. El-behi, M. et al. (2009) J. Immunol. 183:4957.
16. Fitzgerald, D.C. et al. (2007) Nat. Immunol. 8:1372.

Bioinformatics

• Gene Symbol: Il27ra
• Uniprot:
  • O70394()